Screener
Medtronic MDT Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: Medtronic’s 10-K, filed June 18, 2026.
- Filed
- Jun 18, 2026, 4:27 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-044354
| (in millions) | Fiscal Year / 2026 | Fiscal Year / 2025 | Fiscal Year / 2024 |
|---|---|---|---|
| Net income | $4,837 | $4,691 | $3,705 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 2,958 | 2,861 | 2,647 |
| Provision for credit losses | 136 | 123 | 90 |
| Deferred income taxes | 51 | (316) | (508) |
| Stock-based compensation | 457 | 429 | 393 |
| Asset impairments and related inventory write-downs | — | — | 371 |
| Other, net | 314 | 310 | 573 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Medtronic's accounts receivable, credit loss expense (reversal)?
- Medtronic (MDT) reported accounts receivable, credit loss expense (reversal) of $34M in Q1 2026.
- How has Medtronic's accounts receivable, credit loss expense (reversal) changed year-over-year?
- Medtronic's accounts receivable, credit loss expense (reversal) increased by 25.9% year-over-year, from $27M to $34M.
- What is the long-term trend for Medtronic's accounts receivable, credit loss expense (reversal)?
- Over 4 years (2022 to 2026), Medtronic's accounts receivable, credit loss expense (reversal) has grown at a 23.7% compound annual growth rate (CAGR), from $58M to $136M.
Ask your AI about Medtronic's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude